Blue Ligth Emitting Diode in Treatment of Recurring Vulvovaginal Candidiasis: A Case Report

Robatto, Mariana; Pavie, Maria Clara; Tozetto, Sibele de Oliveira; Brito, Milena Bastos; Lordêlo, Patrícia

doi:10.17267/2317-3386bjmhh.v5i4.1472

Cited by 4 publications

(3 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Three sessions were performed, which reduced the fungal load at the end of treatment. Three months after the conclusion of the treatment, the absence of fungal infection was noted [20]. They also observed resolution of the clinical manifestations (pruritus, burning, dysuria, dyspareunia, and edema) of the patient after treatment.…”

Section: Discussionmentioning

confidence: 86%

Ultraviolet A/blue light-emitting diode therapy for vulvovaginal candidiasis: a case presentation

et al. 2019

Self Cite

View full text Add to dashboard Cite

Vulvovaginal candidiasis (VVC) is a frequent infection of the female genitourinary tract. It is considered the second most common genital infection in women, after bacterial vaginosis. VVC is treated with oral or topical azole derivatives. However, these agents may lead to adverse reactions and their chronic use might lead to resistance to antifungal agents. Given that the ultraviolet A/blue light-emitting diode (LED) is an electromagnetic radiation source with antimicrobial properties, it is hypothesized that this resource may be a non-drug alternative to the treatment of vulvovaginitis. A technical/experimental safety test was conducted to characterize the light source spectrum and temperature generation of the device, followed by a pilot study in a 52year-old patient with a clinical diagnosis of VVC confirmed by culture and examination of fresh vaginal samples, owing to the presence of lumpy vaginal discharge and a complaint of pruritus. The vulva and vagina were exposed to 401 ± 5 nm ultraviolet A/ blue LED irradiation in a single session, divided into two applications. A reassessment was performed 21 days after the treatment. The light-emitting device had a visible spectrum, in the violet and blue ranges, and a maximum temperature increase of 7 °C. During the reassessment, the culture was found to be negative for fungus, and the signs and symptoms of the patient had disappeared. A light-emitting device with a spectrum in the range of 401 ± 5 nm could potentially be an alternative treatment modality for women with VVC, as it led to the resolution of clinical and microbiological problems in our patient.

show abstract

Section: Discussionmentioning

confidence: 86%

Ultraviolet A/blue light-emitting diode therapy for vulvovaginal candidiasis: a case presentation

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…These fluences were adjusted after initial experiments based on the study described elsewhere. 24 According to the manufacturer's instructions, a 5-minute break is taken every 10 minutes to allow the instrument to cool. The positive control consists of a yeast suspension in the presence of an antifungal agent with a 50% growth inhibitory concentration (IC50).…”

Section: Leds Applicationmentioning

confidence: 99%

Protocol for evaluating the in vitro effect of violet light-emitting diodes (LEDs) 410 nm ± 10 nm on yeast cultures

et al. 2022

View full text Add to dashboard Cite

BACKGROUND: Candida spp and Malassezia spp cause superficial infections that may be resistant to conventional treatments. Violet light-emitting diodes (LEDs) therapy is a therapeutic alternative. PURPOSE: To describe the protocol for evaluating the antifungal effect of violet LEDs 410 nm ± 10 nm on Candida spp and Malassezia spp in vitro. PROTOCOL: LEDs 410 nm ± 10 nm are applied to a fungal suspension at fluences of 61.13 J/cm2, 91.70 J/cm2, and 183.39 J/cm2. The isolates are cultured for 48 to 72 hours. Colony forming units (CFUs) are quantified by visual counting and percent culture plate occupancy by digital analysis. Morphology is assessed by light microscopy and Gram staining, and yeast metabolism/function by transmission electron microscopy, assessment of reactive oxygen species, and DNA fragmentation. DATA ANALYSIS: the percentage of LEDs inhibition is calculated considering the growth of the negative control condition and the percentage of plate occupancy by yeasts by dividing the number of pixels classified as colonies by the total number of pixels on the plate. The morphological and functional aspects are described for the intervention and negative control. The ANOVA test is used to compare the mean percentages of growth inhibition and plate occupancy between the three fluences of LEDs 410 nm ± 10 nm and the negative control. ESTIMATED RESULTS: We intend to determine the antifungal effect of the different fluences of LEDs 410 nm ± 10 nm on Candida spp and Malassezia spp. The evaluation of other fungal species by this protocol should be investigated.

show abstract

“…9 Research group recently published a case report that demonstrated a response to recurrent vulvovaginal candidiasis and the post-radiation treatment long-term sequelae (in press). 10,11 A clinical trial for recurrent vaginal candidiasis is ongoing. We previously conducted a pilot study with noncancer post-menopause syndrome patients with promising results (in press) with three sessions with a LED device and good tolerance was observed.…”

mentioning

confidence: 99%

Light emitting diode for the treatment of genitourinary syndrome of menopause in breast cancer survivors: study protocol for a double blinded trial

et al. 2021

Self Cite

View full text Add to dashboard Cite

Background: Genitourinary Syndrome of Menopause (GSM) after breast cancer are secondary to many mechanisms such long-term side effects of cancer treatment. Light-Emitting Diode (LED) is a treatment aimed at improving vaginal epithelial tissue. This study will aim to analyze the effects of 405 nm LED on GSM of breast cancer survivors.Methods: This double-blind, randomized clinical trial will be conducted with breast cancer survivors aged 18-65 years, diagnosed with GSM, with at least one sign and one symptom of GSM and vaginal pH≥5 or proven cytologic hypotrophy or atrophy. Pregnant women, those who received hormone replacement within the prior 6 months, with active vaginal infection, impaired comprehension, neurological disease, and progression to metastatic disease during the protocol, will be excluded. LED will be applied intravaginally with gel heated to 38ºC. Each 5/weekly session will last 8 minutes, concurrent with pelvic floor muscle kinesiotherapy. The control group will be treated with the same protocol with LED device turned off. Response will be assessed with the Vaginal Maturation Index analysis, vaginal cytology, and questionnaires to evaluate urinary complains, sexual function, genital self-image and quality of life. Satisfaction will be assessed using a Visual Analog and Likert scale. Measurements will be performed pre-treatment, post-treatment week-3, and month-2 and 3.Conclusions: We aim to identify the benefits of LED for breast cancer survivors with GSM.Trial registration: Clinical trials registration number NCT03833726-version 2.0, July 28, 2019.

show abstract

Blue Ligth Emitting Diode in Treatment of Recurring Vulvovaginal Candidiasis: A Case Report

Cited by 4 publications

References 9 publications

Ultraviolet A/blue light-emitting diode therapy for vulvovaginal candidiasis: a case presentation

Ultraviolet A/blue light-emitting diode therapy for vulvovaginal candidiasis: a case presentation

Protocol for evaluating the in vitro effect of violet light-emitting diodes (LEDs) 410 nm ± 10 nm on yeast cultures

Light emitting diode for the treatment of genitourinary syndrome of menopause in breast cancer survivors: study protocol for a double blinded trial

Contact Info

Product

Resources

About